documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
1,044 rows where docket_id = "FDA-2007-D-0369" and posted_year = 2024 sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, comment_start_date, comment_end_date, open_for_comment, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2007-D-0369-2066 | FDA | None FDA-2007-D-0369 | PSG_216993 - Draft Guidance on Quizartinib Dihydrochloride | Other | Guidance | 2024-11-21T05:00:00Z | 2024 | 11 | 2024-11-21T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:34:51Z | 1 | 0 | 09000064868293cc | |
| FDA-2007-D-0369-2018 | FDA | None FDA-2007-D-0369 | PSG_020833 - Draft Guidance on Fluticasone Propionate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2025-01-17T02:01:11Z | 1 | 0 | 0900006486829349 | |
| FDA-2007-D-0369-2060 | FDA | None FDA-2007-D-0369 | PSG_216632 - Draft Guidance on Adapalene; Benzoyl Peroxide; Clindamycin Phosphate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-12-11T02:01:02Z | 1 | 0 | 09000064868293ca | |
| FDA-2007-D-0369-2012 | FDA | None FDA-2007-D-0369 | PSG_017533-Sus - Draft Guidance on Clonazepam | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T19:55:15Z | 1 | 0 | 0900006486829330 | |
| FDA-2007-D-0369-2013 | FDA | None FDA-2007-D-0369 | PSG_018687 - Draft Guidance on Labetalol Hydrochloride | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T19:59:07Z | 1 | 0 | 0900006486829332 | |
| FDA-2007-D-0369-2021 | FDA | None FDA-2007-D-0369 | PSG_021190 - Draft Guidance on Buspirone Hydrochloride | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:08:24Z | 1 | 0 | 0900006486829350 | |
| FDA-2007-D-0369-2022 | FDA | None FDA-2007-D-0369 | PSG_021359 - Draft Guidance on Nitroglycerin | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:08:59Z | 1 | 0 | 0900006486829357 | |
| FDA-2007-D-0369-2057 | FDA | None FDA-2007-D-0369 | PSG_215830 - Draft Guidance on Ritlecitinib Tosylate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:28:25Z | 1 | 0 | 09000064868293c3 | |
| FDA-2007-D-0369-2053 | FDA | None FDA-2007-D-0369 | PSG_215179 - Draft Guidance on Pemetrexed Disodium | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:26:20Z | 1 | 0 | 09000064868293b4 | |
| FDA-2007-D-0369-2015 | FDA | None FDA-2007-D-0369 | PSG_020281 - Draft Guidance on Tramadol Hydrochloride | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T20:00:27Z | 1 | 0 | 0900006486829336 | |
| FDA-2007-D-0369-2007 | FDA | None FDA-2007-D-0369 | PSG_009170 - Draft Guidance on Primidone | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T19:52:32Z | 1 | 0 | 0900006486829323 | |
| FDA-2007-D-0369-2006 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2024-11-21T19:50:01Z | 2024-27048 | 0 | 0 | 0900006486829e19 | |
| FDA-2007-D-0369-2027 | FDA | None FDA-2007-D-0369 | PSG_021641 - Draft Guidance on Rasagiline Mesylate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:11:57Z | 1 | 0 | 0900006486829361 | |
| FDA-2007-D-0369-2026 | FDA | None FDA-2007-D-0369 | PSG_021487-ODT - Draft Guidance on Memantine Hydrochloride | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:11:26Z | 1 | 0 | 090000648682935f | |
| FDA-2007-D-0369-2038 | FDA | None FDA-2007-D-0369 | PSG_087954 - Draft Guidance on Phytonadione | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:18:05Z | 1 | 0 | 0900006486829381 | |
| FDA-2007-D-0369-2040 | FDA | None FDA-2007-D-0369 | PSG_203491 - Draft Guidance on Nepafenac | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:19:09Z | 1 | 0 | 0900006486829385 | |
| FDA-2007-D-0369-2056 | FDA | None FDA-2007-D-0369 | PSG_215559 - Draft Guidance on Palovarotene | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:27:51Z | 1 | 0 | 09000064868293c1 | |
| FDA-2007-D-0369-2051 | FDA | None FDA-2007-D-0369 | PSG_213674 - Draft Guidance on Enzalutamide | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:25:08Z | 1 | 0 | 09000064868293a6 | |
| FDA-2007-D-0369-2064 | FDA | None FDA-2007-D-0369 | PSG_217469 - Draft Guidance on Cyclosporine | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:33:49Z | 1 | 0 | 09000064868293de | |
| FDA-2007-D-0369-2050 | FDA | None FDA-2007-D-0369 | PSG_213586 - Draft Guidance on Risperidone | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:24:37Z | 1 | 0 | 09000064868293a4 | |
| FDA-2007-D-0369-2010 | FDA | None FDA-2007-D-0369 | PSG_016084 - Draft Guidance on Allopurinol | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T19:54:11Z | 1 | 0 | 0900006486829329 | |
| FDA-2007-D-0369-2020 | FDA | None FDA-2007-D-0369 | PSG_021184-Cre-0.05P - Draft Guidance on Tazarotene | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:07:46Z | 1 | 0 | 090000648682934e | |
| FDA-2007-D-0369-2024 | FDA | None FDA-2007-D-0369 | PSG_021470 - Draft Guidance on Azelaic Acid | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:10:13Z | 1 | 0 | 090000648682935b | |
| FDA-2007-D-0369-2033 | FDA | None FDA-2007-D-0369 | PSG_022341 - Draft Guidance on Liraglutide | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:15:06Z | 1 | 0 | 0900006486829376 | |
| FDA-2007-D-0369-2014 | FDA | None FDA-2007-D-0369 | PSG_020216 - Draft Guidance on Estrogens, Conjugated | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2025-09-15T09:00:17Z | 1 | 0 | 0900006486829334 | |
| FDA-2007-D-0369-2048 | FDA | None FDA-2007-D-0369 | PSG_211728 - Draft Guidance on Mitomycin | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2025-03-06T02:00:19Z | 1 | 0 | 09000064868293a0 | |
| FDA-2007-D-0369-2042 | FDA | None FDA-2007-D-0369 | PSG_205641 - Draft Guidance on Mometasone Furoate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2025-01-17T02:01:11Z | 1 | 0 | 0900006486829389 | |
| FDA-2007-D-0369-2016 | FDA | None FDA-2007-D-0369 | PSG_020692 - Draft Guidance on Salmeterol Xinafoate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2025-01-17T02:01:10Z | 1 | 0 | 0900006486829345 | |
| FDA-2007-D-0369-2023 | FDA | None FDA-2007-D-0369 | PSG_021395 - Draft Guidance on Tiotropium Bromide | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2025-01-17T02:00:59Z | 1 | 0 | 0900006486829359 | |
| FDA-2007-D-0369-2049 | FDA | None FDA-2007-D-0369 | PSG_212905 - Draft Guidance on Cantharidin | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:24:04Z | 1 | 0 | 09000064868293a2 | |
| FDA-2007-D-0369-2058 | FDA | None FDA-2007-D-0369 | PSG_216338 - Draft Guidance on Paclitaxel | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:28:54Z | 1 | 0 | 09000064868293c5 | |
| FDA-2007-D-0369-2039 | FDA | None FDA-2007-D-0369 | PSG_203159 - Draft Guidance on Levonorgestrel | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:18:39Z | 1 | 0 | 0900006486829383 | |
| FDA-2007-D-0369-2046 | FDA | None FDA-2007-D-0369 | PSG_210251 - Draft Guidance on Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide Fumarate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:22:28Z | 1 | 0 | 090000648682939c | |
| FDA-2007-D-0369-2059 | FDA | None FDA-2007-D-0369 | PSG_216387 - Draft Guidance on Acalabrutinib Maleate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:29:28Z | 1 | 0 | 09000064868293c7 | |
| FDA-2007-D-0369-2035 | FDA | None FDA-2007-D-0369 | PSG_050065 - Draft Guidance on Dexamethasone; Neomycin Sulfate; Polymyxin B Sulfate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:16:09Z | 1 | 0 | 090000648682937a | |
| FDA-2007-D-0369-2061 | FDA | None FDA-2007-D-0369 | PSG_217006 - Draft Guidance on Aripiprazole | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:32:15Z | 1 | 0 | 09000064868293ce | |
| FDA-2007-D-0369-2063 | FDA | None FDA-2007-D-0369 | PSG_217388 - Draft Guidance on Eplontersen Sodium | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:33:17Z | 1 | 0 | 09000064868293d2 | |
| FDA-2007-D-0369-2025 | FDA | None FDA-2007-D-0369 | PSG_021481 - Draft Guidance on Enfuvirtide | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:10:50Z | 1 | 0 | 090000648682935d | |
| FDA-2007-D-0369-2041 | FDA | None FDA-2007-D-0369 | PSG_203565 - Draft Guidance on Ferric Carboxymaltose | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2025-06-05T09:00:09Z | 1 | 0 | 0900006486829387 | |
| FDA-2007-D-0369-2055 | FDA | None FDA-2007-D-0369 | PSG_215344 - Draft Guidance on Magnesium Sulfate; Polyethylene Glycol 3350; Potassium Chloride; Sodium Chloride; Sodium Sulfate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:27:21Z | 1 | 0 | 09000064868293bf | |
| FDA-2007-D-0369-2036 | FDA | None FDA-2007-D-0369 | PSG_050777 - Draft Guidance on Tacrolimus | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:16:54Z | 1 | 0 | 090000648682937c | |
| FDA-2007-D-0369-2037 | FDA | None FDA-2007-D-0369 | PSG_083722 - Draft Guidance on Phytonadione | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:17:26Z | 1 | 0 | 090000648682937e | |
| FDA-2007-D-0369-2054 | FDA | None FDA-2007-D-0369 | PSG_215309 - Draft Guidance on Ruxolitinib Phosphate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:26:49Z | 1 | 0 | 09000064868293b6 | |
| FDA-2007-D-0369-2009 | FDA | None FDA-2007-D-0369 | PSG_011745 - Draft Guidance on Phytonadione | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T19:53:37Z | 1 | 0 | 0900006486829327 | |
| FDA-2007-D-0369-2011 | FDA | None FDA-2007-D-0369 | PSG_016084-Sus - Draft Guidance on Allopurinol | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T19:54:42Z | 1 | 0 | 090000648682932e | |
| FDA-2007-D-0369-2028 | FDA | None FDA-2007-D-0369 | PSG_021862 - Draft Guidance on Nepafenac | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:12:29Z | 1 | 0 | 0900006486829363 | |
| FDA-2007-D-0369-2065 | FDA | None FDA-2007-D-0369 | PSG_218490 - Draft Guidance on Macitentan; Tadalafil | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:34:21Z | 1 | 0 | 09000064868293e0 | |
| FDA-2007-D-0369-2044 | FDA | None FDA-2007-D-0369 | PSG_208558 - Draft Guidance on Olaparib | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:21:24Z | 1 | 0 | 0900006486829398 | |
| FDA-2007-D-0369-2034 | FDA | None FDA-2007-D-0369 | PSG_022518 - Draft Guidance on Formoterol Fumarate; Mometasone Furoate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2025-01-17T02:01:10Z | 1 | 0 | 0900006486829378 | |
| FDA-2007-D-0369-2031 | FDA | None FDA-2007-D-0369 | PSG_022150 - Draft Guidance on Icatibant Acetate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:14:05Z | 1 | 0 | 0900006486829367 | |
| FDA-2007-D-0369-2032 | FDA | None FDA-2007-D-0369 | PSG_022180 - Draft Guidance on Ferumoxytol | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:14:36Z | 1 | 0 | 0900006486829369 | |
| FDA-2007-D-0369-2030 | FDA | None FDA-2007-D-0369 | PSG_020386 - Draft Guidance on Losartan Potassium | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:13:34Z | 1 | 0 | 0900006486829343 | |
| FDA-2007-D-0369-2047 | FDA | None FDA-2007-D-0369 | PSG_211413 - Draft Guidance on Cefazolin Sodium | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:23:01Z | 1 | 0 | 090000648682939e | |
| FDA-2007-D-0369-2043 | FDA | None FDA-2007-D-0369 | PSG_206947 - Draft Guidance on Lenvatinib Mesylate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:20:49Z | 1 | 0 | 0900006486829396 | |
| FDA-2007-D-0369-2008 | FDA | None FDA-2007-D-0369 | PSG_010104 - Draft Guidance on Phytonadione | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T19:53:05Z | 1 | 0 | 0900006486829325 | |
| FDA-2007-D-0369-2062 | FDA | None FDA-2007-D-0369 | PSG_217064 - Draft Guidance on Phentolamine Mesylate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2024-11-21T21:32:46Z | 1 | 0 | 09000064868293d0 | |
| FDA-2007-D-0369-2017 | FDA | None FDA-2007-D-0369 | PSG_020831 - Draft Guidance on Formoterol Fumarate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2025-01-17T02:01:07Z | 1 | 0 | 0900006486829347 | |
| FDA-2007-D-0369-2019 | FDA | None FDA-2007-D-0369 | PSG_021077 - Draft Guidance on Fluticasone Propionate; Salmeterol Xinafoate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2025-01-17T02:01:14Z | 1 | 0 | 090000648682934b | |
| FDA-2007-D-0369-2029 | FDA | None FDA-2007-D-0369 | PSG_021929 - Draft Guidance on Budesonide; Formoterol Fumarate Dihydrate | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2025-01-17T02:01:10Z | 1 | 0 | 0900006486829365 | |
| FDA-2007-D-0369-2052 | FDA | None FDA-2007-D-0369 | PSG_214324 - Draft Guidance on Treprostinil | Other | Guidance | 2024-11-20T05:00:00Z | 2024 | 11 | 2024-11-20T05:00:00Z | 2025-01-22T04:59:59Z | 2025-01-17T02:01:14Z | 1 | 0 | 09000064868293a8 | |
| FDA-2007-D-0369-2045 | FDA | None FDA-2007-D-0369 | PSG_209830 - Draft Guidance on Aripiprazole Lauroxil | Other | Guidance | 2024-11-20T00:00:00Z | 2024 | 11 | 2024-11-20T00:00:00Z | 2025-01-22T04:59:59Z | 2025-05-09T01:17:15Z | 1 | 0 | 090000648682939a | |
| FDA-2007-D-0369-2004 | FDA | None FDA-2007-D-0369 | PSG_078690 - Draft Guidance on Carbidopa; Levodopa | Other | Guidance | 2024-11-14T05:00:00Z | 2024 | 11 | 2024-11-14T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-14T21:10:46Z | 1 | 0 | 090000648681414e | |
| FDA-2007-D-0369-2003 | FDA | None FDA-2007-D-0369 | PSG_011808 - Draft Guidance on Thioridazine Hydrochloride | Other | Guidance | 2024-11-14T05:00:00Z | 2024 | 11 | 2024-11-14T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-14T21:10:38Z | 1 | 0 | 09000064867f21ca | |
| FDA-2007-D-0369-1995 | FDA | None FDA-2007-D-0369 | PSG_209899 - Draft Guidance on Ozanimod Hydrochloride | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T20:56:51Z | 1 | 0 | 09000064867f2d7d | |
| FDA-2007-D-0369-1954 | FDA | None FDA-2007-D-0369 | PSG_050759 - Draft Guidance on Mycophenolate Mofetil | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T12:54:37Z | 1 | 0 | 09000064867f240b | |
| FDA-2007-D-0369-1972 | FDA | None FDA-2007-D-0369 | PSG_083976 - Draft Guidance on Methyltestosterone | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T12:54:47Z | 1 | 0 | 09000064867f242f | |
| FDA-2007-D-0369-1981 | FDA | None FDA-2007-D-0369 | PSG_200175 - Draft Guidance on Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T12:54:53Z | 1 | 0 | 09000064867f2441 | |
| FDA-2007-D-0369-1983 | FDA | None FDA-2007-D-0369 | PSG_201280 - Draft Guidance on Linagliptin | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T12:54:54Z | 1 | 0 | 09000064867f2445 | |
| FDA-2007-D-0369-1953 | FDA | None FDA-2007-D-0369 | PSG_050725 - Draft Guidance on Amoxicillin; Clavulanate Potassium | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T12:54:36Z | 1 | 0 | 09000064867f2409 | |
| FDA-2007-D-0369-1986 | FDA | None FDA-2007-D-0369 | PSG_201373 - Draft Guidance on Fexofenadine Hydrochloride | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T12:54:56Z | 1 | 0 | 09000064867f244b | |
| FDA-2007-D-0369-1957 | FDA | None FDA-2007-D-0369 | PSG_050722 - Draft Guidance on Mycophenolate Mofetil | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T12:54:38Z | 1 | 0 | 09000064867f2411 | |
| FDA-2007-D-0369-1975 | FDA | None FDA-2007-D-0369 | PSG_200534 - Draft Guidance on Oxycodone Hydrochloride | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T12:54:49Z | 1 | 0 | 09000064867f2435 | |
| FDA-2007-D-0369-1889 | FDA | None FDA-2007-D-0369 | PSG_022344 - Draft Guidance on Lamivudine; Tenofovir Disoproxil Fumara | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:44:53Z | 1 | 0 | 09000064867f237f | |
| FDA-2007-D-0369-1941 | FDA | None FDA-2007-D-0369 | PSG_050542 - Draft Guidance on Amoxicillin | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:11Z | 1 | 0 | 09000064867f23f1 | |
| FDA-2007-D-0369-1938 | FDA | None FDA-2007-D-0369 | PSG_050662 - Draft Guidance on Clarithromycin | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:10Z | 1 | 0 | 09000064867f23eb | |
| FDA-2007-D-0369-1893 | FDA | None FDA-2007-D-0369 | PSG_022363 - Draft Guidance on Pitavastatin Calcium | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:44:57Z | 1 | 0 | 09000064867f2391 | |
| FDA-2007-D-0369-1936 | FDA | None FDA-2007-D-0369 | PSG_050641-Cap-150MG - Draft Guidance on Doxycycline | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:08Z | 1 | 0 | 09000064867f23e7 | |
| FDA-2007-D-0369-1797 | FDA | None FDA-2007-D-0369 | PSG_019915 - Draft Guidance on Fosinopril Sodium | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:25Z | 1 | 0 | 09000064867ee4fa | |
| FDA-2007-D-0369-1817 | FDA | None FDA-2007-D-0369 | PSG_020251 - Draft Guidance on Ranitidine Hydrochloride | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:29Z | 1 | 0 | 09000064867f2123 | |
| FDA-2007-D-0369-1822 | FDA | None FDA-2007-D-0369 | PSG_020180 - Draft Guidance on Finasteride | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:32Z | 1 | 0 | 09000064867f212d | |
| FDA-2007-D-0369-1832 | FDA | None FDA-2007-D-0369 | PSG_020264 - Draft Guidance on Megestrol Acetate | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:33Z | 1 | 0 | 09000064867f2141 | |
| FDA-2007-D-0369-1836 | FDA | None FDA-2007-D-0369 | PSG_020286 - Draft Guidance on Fosinopril Sodium; Hydrochlorothiazide | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:35Z | 1 | 0 | 09000064867f2149 | |
| FDA-2007-D-0369-1839 | FDA | None FDA-2007-D-0369 | PSG_020297 - Draft Guidance on Carvedilol | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:35Z | 1 | 0 | 09000064867f214f | |
| FDA-2007-D-0369-1843 | FDA | None FDA-2007-D-0369 | PSG_020397 - Draft Guidance on Tizanidine Hydrochloride | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:36Z | 1 | 0 | 09000064867f2157 | |
| FDA-2007-D-0369-1858 | FDA | None FDA-2007-D-0369 | PSG_020528 - Draft Guidance on Trandolapril | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:39Z | 1 | 0 | 09000064867f2175 | |
| FDA-2007-D-0369-1871 | FDA | None FDA-2007-D-0369 | PSG_020702 - Draft Guidance on Atorvastatin Calcium | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:42Z | 1 | 0 | 09000064867f2190 | |
| FDA-2007-D-0369-1876 | FDA | None FDA-2007-D-0369 | PSG_020713 - Draft Guidance on Desogestrel; Ethinyl Estradiol | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:45Z | 1 | 0 | 09000064867f219a | |
| FDA-2007-D-0369-1877 | FDA | None FDA-2007-D-0369 | PSG_020717 - Draft Guidance on Modafinil | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:45Z | 1 | 0 | 09000064867f219c | |
| FDA-2007-D-0369-1879 | FDA | None FDA-2007-D-0369 | PSG_020658 - Draft Guidance on Ropinirole Hydrochloride | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:45Z | 1 | 0 | 09000064867f21a0 | |
| FDA-2007-D-0369-1882 | FDA | None FDA-2007-D-0369 | PSG_020636 - Draft Guidance on Nevirapine | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:46Z | 1 | 0 | 09000064867f21b0 | |
| FDA-2007-D-0369-1884 | FDA | None FDA-2007-D-0369 | PSG_020704 - Draft Guidance on Loratadine | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T22:45:46Z | 1 | 0 | 09000064867f21b4 | |
| FDA-2007-D-0369-1944 | FDA | None FDA-2007-D-0369 | PSG_050665 - Draft Guidance on Cefprozil | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-14T13:15:12Z | 1 | 0 | 09000064867f23f7 | |
| FDA-2007-D-0369-1991 | FDA | None FDA-2007-D-0369 | PSG_009838 - Draft Guidance on Reserpine | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-13T16:42:38Z | 1 | 0 | 09000064867ee375 | |
| FDA-2007-D-0369-1802 | FDA | None FDA-2007-D-0369 | PSG_019906 - Draft Guidance on Clomipramine Hydrochloride | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-13T19:22:23Z | 1 | 0 | 09000064867f2105 | |
| FDA-2007-D-0369-1840 | FDA | None FDA-2007-D-0369 | PSG_020448 - Draft Guidance on Loperamide Hydrochloride | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-13T19:29:13Z | 1 | 0 | 09000064867f2151 | |
| FDA-2007-D-0369-1883 | FDA | None FDA-2007-D-0369 | PSG_020667 - Draft Guidance on Pramipexole Dihydrochloride | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-13T19:42:00Z | 1 | 0 | 09000064867f21b2 | |
| FDA-2007-D-0369-1897 | FDA | None FDA-2007-D-0369 | PSG_022565 - Draft Guidance on Ibuprofen; Phenylephrine Hydrochloride | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2025-11-17T10:00:09Z | 1 | 0 | 09000064867f2399 | |
| FDA-2007-D-0369-1965 | FDA | None FDA-2007-D-0369 | PSG_083266 - Draft Guidance on Estrogens, Esterified | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T12:54:43Z | 1 | 0 | 09000064867f2421 | |
| FDA-2007-D-0369-1966 | FDA | None FDA-2007-D-0369 | PSG_050749 - Draft Guidance on Cefdinir | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T12:54:44Z | 1 | 0 | 09000064867f2423 | |
| FDA-2007-D-0369-1950 | FDA | None FDA-2007-D-0369 | PSG_062279 - Draft Guidance on Griseofulvin, Microcrystalline; Griseofulvin, Microsize | Other | Guidance | 2024-11-12T05:00:00Z | 2024 | 11 | 2024-11-12T05:00:00Z | 2024-12-31T04:59:59Z | 2024-11-12T12:54:35Z | 1 | 0 | 09000064867f2403 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;